126 related articles for article (PubMed ID: 37969054)
21. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
[TBL] [Abstract][Full Text] [Related]
22. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
23. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
[TBL] [Abstract][Full Text] [Related]
24. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
[TBL] [Abstract][Full Text] [Related]
25. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
Neuendorff NR; Schwarz M; Hemmati P; Türkmen S; Bommer C; Burmeister T; Dörken B; le Coutre P; Arnold R; Westermann J
Acta Haematol; 2015; 133(2):237-41. PubMed ID: 25401297
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring
Pan W; Zhao X; Shi W; Jiang Z; Xiao H
Leuk Lymphoma; 2020 Nov; 61(11):2756-2759. PubMed ID: 33167720
[No Abstract] [Full Text] [Related]
28. Rare BCR-ABL1 transcript in a RUNX1-RUNX1T1-positive de novo acute myeloid leukemia: The chicken and egg tale.
Gupta R; Mittal N; Rahman K; Sharma A; Singh P; Kumar S; Nityanand S
Int J Lab Hematol; 2018 Apr; 40(2):e24-e27. PubMed ID: 29393574
[No Abstract] [Full Text] [Related]
29. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
30. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
[TBL] [Abstract][Full Text] [Related]
31. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML.
Musani R; Chang H
Blood; 2021 May; 137(20):2853. PubMed ID: 34014289
[No Abstract] [Full Text] [Related]
33. Lymphoid blasts with aberrant myeloid marker expression and BCR/ABL1: Is it mixed phenotype acute leukemia or B lymphoblastic leukemia?
Shopsowitz KE; Shah K; Tsui H
Cytometry B Clin Cytom; 2022 Jan; 102(1):73-75. PubMed ID: 33780164
[No Abstract] [Full Text] [Related]
34. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
Konoplev S; Yin CC; Kornblau SM; Kantarjian HM; Konopleva M; Andreeff M; Lu G; Zuo Z; Luthra R; Medeiros LJ; Bueso-Ramos CE
Leuk Lymphoma; 2013 Jan; 54(1):138-44. PubMed ID: 22691121
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract][Full Text] [Related]
36. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
37. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
[TBL] [Abstract][Full Text] [Related]
38. MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations.
Hua X; Hyland PL; Huang J; Song L; Zhu B; Caporaso NE; Landi MT; Chatterjee N; Shi J
Am J Hum Genet; 2016 Mar; 98(3):442-455. PubMed ID: 26899600
[TBL] [Abstract][Full Text] [Related]
39. Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia.
Raikar SS; Scarborough JD; Sabnis H; Bergsagel J; Wu D; Cooper TM; Keller FG; Wood BL; Bunting ST
Pediatr Blood Cancer; 2016 Sep; 63(9):1667-70. PubMed ID: 27145535
[TBL] [Abstract][Full Text] [Related]
40. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
